JP6971850B2 - がんの併用療法 - Google Patents

がんの併用療法 Download PDF

Info

Publication number
JP6971850B2
JP6971850B2 JP2017553118A JP2017553118A JP6971850B2 JP 6971850 B2 JP6971850 B2 JP 6971850B2 JP 2017553118 A JP2017553118 A JP 2017553118A JP 2017553118 A JP2017553118 A JP 2017553118A JP 6971850 B2 JP6971850 B2 JP 6971850B2
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
csf1r
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512430A (ja
JP2018512430A5 (cg-RX-API-DMAC7.html
Inventor
エマ マステラー，
トーマス ブレナン，
デーヴィッド ベロヴィン，
ケヴィン ベイカー，
ブライアン ウォン，
Original Assignee
ファイヴ プライム セラピューティクス インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイヴ プライム セラピューティクス インク filed Critical ファイヴ プライム セラピューティクス インク
Publication of JP2018512430A publication Critical patent/JP2018512430A/ja
Publication of JP2018512430A5 publication Critical patent/JP2018512430A5/ja
Application granted granted Critical
Publication of JP6971850B2 publication Critical patent/JP6971850B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017553118A 2015-04-13 2016-04-12 がんの併用療法 Active JP6971850B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562146766P 2015-04-13 2015-04-13
US62/146,766 2015-04-13
US201562190945P 2015-07-10 2015-07-10
US62/190,945 2015-07-10
PCT/US2016/027038 WO2016168149A1 (en) 2015-04-13 2016-04-12 Combination therapy for cancer

Publications (3)

Publication Number Publication Date
JP2018512430A JP2018512430A (ja) 2018-05-17
JP2018512430A5 JP2018512430A5 (cg-RX-API-DMAC7.html) 2019-05-23
JP6971850B2 true JP6971850B2 (ja) 2021-11-24

Family

ID=55809223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553118A Active JP6971850B2 (ja) 2015-04-13 2016-04-12 がんの併用療法

Country Status (22)

Country Link
US (2) US20180085472A1 (cg-RX-API-DMAC7.html)
EP (2) EP3964527A3 (cg-RX-API-DMAC7.html)
JP (1) JP6971850B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170135924A (cg-RX-API-DMAC7.html)
CN (2) CN107709365A (cg-RX-API-DMAC7.html)
AU (1) AU2016249981B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017020952A2 (cg-RX-API-DMAC7.html)
CA (1) CA2980460A1 (cg-RX-API-DMAC7.html)
CY (1) CY1123972T1 (cg-RX-API-DMAC7.html)
DK (1) DK3283527T3 (cg-RX-API-DMAC7.html)
ES (1) ES2857076T3 (cg-RX-API-DMAC7.html)
HU (1) HUE053903T2 (cg-RX-API-DMAC7.html)
IL (1) IL254705B (cg-RX-API-DMAC7.html)
LT (1) LT3283527T (cg-RX-API-DMAC7.html)
MX (1) MX388015B (cg-RX-API-DMAC7.html)
PL (1) PL3283527T3 (cg-RX-API-DMAC7.html)
PT (1) PT3283527T (cg-RX-API-DMAC7.html)
RS (1) RS61531B1 (cg-RX-API-DMAC7.html)
SI (1) SI3283527T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100132T1 (cg-RX-API-DMAC7.html)
TW (1) TWI725966B (cg-RX-API-DMAC7.html)
WO (1) WO2016168149A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
JP6621252B2 (ja) * 2015-06-17 2019-12-18 国立大学法人北海道大学 治療耐性がんに対する治療耐性低減剤
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018144334A1 (en) * 2017-02-02 2018-08-09 Imclone Llc Dosing regimen for anti-csf-1r antibody
CA3054132A1 (en) * 2017-02-27 2018-08-30 Shattuck Labs, Inc. Csf1r-based chimeric proteins
JP2020510673A (ja) * 2017-03-03 2020-04-09 ヤンセン バイオテツク，インコーポレーテツド がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
WO2018183366A1 (en) * 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
WO2018183608A1 (en) * 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
JP2020517256A (ja) * 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
WO2018219327A1 (zh) * 2017-06-01 2018-12-06 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
SG11202100096XA (en) * 2018-07-09 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to ilt4
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
AU2019346645A1 (en) * 2018-09-27 2021-04-29 Marengo Therapeutics, Inc. CSF1R/CCR2 multispecific antibodies
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
BR112021010414A2 (pt) * 2018-11-30 2021-09-08 Jiangsu Hengrui Medicine Co., Ltd. Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas
EP3892634A4 (en) * 2018-11-30 2022-11-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
EP3935391B1 (en) * 2019-03-05 2024-04-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarkers for renal cell carcinoma
JP7535060B2 (ja) * 2019-04-10 2024-08-15 ナンカイ ユニバーシティ 抗ｃｄ４０抗体およびその使用
TW202112812A (zh) * 2019-05-24 2021-04-01 香港商安立璽榮生醫(香港)有限公司 Csf1r抗體、il10融合蛋白及其用途
CN110904229B (zh) * 2019-11-25 2020-09-29 济南市中心医院 Ilt4在肿瘤诊治中的应用
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
WO2021142573A1 (zh) * 2020-01-13 2021-07-22 丁邦 一种融合蛋白及其制法和用途
WO2021262597A2 (en) 2020-06-22 2021-12-30 Ngm Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
WO2022117870A1 (en) * 2020-12-04 2022-06-09 Universiteit Antwerpen Combination immunotherapy of il-15 and cd40 agonist in cancer treatment
CN112979749A (zh) * 2021-02-26 2021-06-18 深圳海创生物科技有限公司 一种活性环肽、活性环肽组合物及其在制备具有抗氧化作用或抗衰老作用的产品中的应用
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
WO2024073111A2 (en) * 2022-09-30 2024-04-04 Adicet Therapeutics, Inc. Affinity binding entities directed to b7h6 and methods of use thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2518911B2 (ja) 1987-10-23 1996-07-31 森永乳業株式会社 ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5866114A (en) 1992-06-09 1999-02-02 Chiron Corporation Crystallization of M-CSFα
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
PT1223980E (pt) 1999-10-28 2003-10-31 Reinhold Hofbauer Utilizacao de inibidores de csf-1
WO2001034177A2 (en) 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
AU2002314495A1 (en) 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
DE60332483D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SI1638941T1 (sl) 2003-05-22 2010-11-30 Abbott Lab Inhibitorji indazol benzizoksazol in benzizotiazol kinaze
NZ547279A (en) 2003-10-22 2008-04-30 Keck Graduate Inst Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
JP2007524671A (ja) 2004-01-21 2007-08-30 カイロン コーポレイション Ｍ−ｃｓｆムテインおよびその使用
CA2565974A1 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP1778842B8 (en) 2004-07-22 2012-03-21 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
DE602006011574D1 (de) 2005-01-27 2010-02-25 Five Prime Therapeutics Inc Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SG195607A1 (en) 2005-05-10 2013-12-30 Incyte Corp Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US8303955B2 (en) 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
AU2006320858A1 (en) * 2005-11-10 2007-06-07 Receptor Biologix, Inc. Methods for production of receptor and ligand isoforms
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
WO2007075933A2 (en) * 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
EP1977238B1 (en) 2005-12-22 2016-09-28 Novartis AG Soluble human m-csf receptor and uses thereof
WO2007081879A2 (en) 2006-01-05 2007-07-19 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP2064207B1 (en) 2006-09-19 2013-11-06 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US8071581B2 (en) * 2006-10-23 2011-12-06 Sgx Pharmaceuticals, Inc. Triazolopyridazine protein kinase modulators
WO2008060610A2 (en) 2006-11-17 2008-05-22 Biogen Idec Ma Inc. Systemic administration of colony stimulating factors to treat amyloid associated disorders
ATE494306T1 (de) 2007-02-14 2011-01-15 Vaccinex Inc Humanisierte anti-cd100-antikörper
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2008150383A1 (en) 2007-05-30 2008-12-11 Albert Einstein College Of Medicine Of Yeshiva University Csf-1r mutants
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
SG10201500328QA (en) 2007-08-21 2015-03-30 Amgen Inc Human c-fms antigen binding proteins
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AU2008318656A1 (en) 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to FMS treatment
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
ES2573641T3 (es) 2008-01-03 2016-06-09 Université D'aix-Marseille Triterapia utilizable para el tratamiento de un paciente infectado por VIH
RU2547586C2 (ru) 2008-03-14 2015-04-10 Трансжене С.А. Антитело против csf-1r
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
EP2271672B1 (en) * 2008-03-26 2015-11-11 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
MX2010012064A (es) 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
WO2010001617A1 (en) 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
HUE026201T2 (en) 2009-12-10 2016-05-30 Hoffmann La Roche Antibodies binding to human CSF1R extracellular domain 4 and their use
GEP201706660B (en) 2010-03-04 2017-04-25 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
RU2617966C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
CA2797399C (en) * 2010-05-04 2021-03-02 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
WO2012062218A1 (en) 2010-11-11 2012-05-18 The University Of Hong Kong Soluble pd-1 variants, fusion constructs, and uses thereof
WO2012082573A1 (en) 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
CA2851771C (en) 2011-10-21 2018-09-11 Transgene Sa Modulation of macrophage activation
EP2768861A1 (en) 2011-10-21 2014-08-27 Institut National de la Sante et de la Recherche Medicale (INSERM) A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CA2871445C (en) 2012-05-11 2020-07-07 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
RU2718751C2 (ru) 2012-08-31 2020-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
US9724341B2 (en) 2013-07-11 2017-08-08 Alexza Pharmaceuticals, Inc. Nicotine salt with meta-salicylic acid
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
HRP20210440T1 (hr) 2014-10-29 2021-04-30 Five Prime Therapeutics, Inc. Kombinirana terapija za rak

Also Published As

Publication number Publication date
US11559583B2 (en) 2023-01-24
EP3964527A3 (en) 2022-06-15
EP3283527A1 (en) 2018-02-21
BR112017020952A2 (pt) 2018-07-10
LT3283527T (lt) 2021-03-25
US20200237927A1 (en) 2020-07-30
HUE053903T2 (hu) 2021-07-28
PT3283527T (pt) 2021-03-03
TW201702270A (zh) 2017-01-16
US20180085472A1 (en) 2018-03-29
SMT202100132T1 (it) 2021-05-07
WO2016168149A1 (en) 2016-10-20
TWI725966B (zh) 2021-05-01
AU2016249981B2 (en) 2022-02-17
DK3283527T3 (da) 2021-03-08
SI3283527T1 (sl) 2021-04-30
KR20170135924A (ko) 2017-12-08
MX2017013178A (es) 2018-03-01
IL254705A0 (en) 2017-11-30
MX388015B (es) 2025-03-19
PL3283527T3 (pl) 2021-06-14
CA2980460A1 (en) 2016-10-20
JP2018512430A (ja) 2018-05-17
ES2857076T3 (es) 2021-09-28
CN114681608A (zh) 2022-07-01
EP3283527B1 (en) 2021-01-13
CY1123972T1 (el) 2022-05-27
AU2016249981A1 (en) 2017-10-12
CN107709365A (zh) 2018-02-16
RS61531B1 (sr) 2021-04-29
IL254705B (en) 2021-07-29
EP3964527A2 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
JP6971850B2 (ja) がんの併用療法
JP2025108413A (ja) Ｐｓｇｌ－１アンタゴニスト及びその使用
ES2899616T3 (es) Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central
JP7719799B2 (ja) 抗ガレクチン－９抗体およびその使用
EP4367140A1 (en) Anti-tnfr2 antibody and uses thereof
TWI867138B (zh) 抗tnfr2抗體及其用途
KR20220151161A (ko) Igsf8의 표적화에 의해 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
CN110709420A (zh) 使用抗gitr抗体的癌症组合疗法
EA039894B1 (ru) Способ лечения рака, композиция для лечения рака, применение композиции для получения лекарственного средства для лечения рака, характеризующегося присутствием макрофагов, экспрессирующих csf1r

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211012

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211102

R150 Certificate of patent or registration of utility model

Ref document number: 6971850

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250